NEXTBio Capital Management LP: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 2038158) · Explore on the interactive board
NEXTBio Capital Management LP disclosed 22 US equity positions worth $217.4m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is PTGX at 12.4% of the reported book, followed by STTK, CMPS. The top ten holdings are 77.7% of the book, and the portfolio behaves like about 13 equal-weight positions. Versus the prior filing it opened 3 new positions, added to 7, reduced 4 and exited 5. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does NEXTBio Capital Management LP own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 3 new, 7 added, 4 reduced, 5 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 12.4% | $26.9m | 219,333 | -4% | reduced |
| 2 | STTK SHATTUCK LABS INC | Healthcare | 11.9% | $25.9m | 3,727,348 | 18% | added |
| 3 | CMPS COMPASS PATHWAYS PLC | Healthcare | 11.6% | $25.1m | 1,775,759 | -12% | reduced |
| 4 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 7.7% | $16.8m | 312,496 | 135% | added |
| 5 | VOR VOR BIOPHARMA INC | Healthcare | 7.5% | $16.4m | 889,164 | -11% | reduced |
| 6 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 6.7% | $14.6m | 131,758 | 5% | added |
| 7 | PVLA PALVELLA THERAPEUTICS INC NE | Healthcare | 6.3% | $13.7m | 89,909 | 9% | added |
| 8 | XENE XENON PHARMACEUTICALS INC | Healthcare | 5.1% | $11.1m | 183,225 | 0% | held |
| 9 | ZBIO ZENAS BIOPHARMA INC | 5.0% | $10.8m | 426,736 | 0% | held | |
| 10 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 3.5% | $7.6m | 706,124 | 35% | added |
| 11 | IVA INVENTIVA SA | 3.1% | $6.8m | 1,787,984 | 34% | added | |
| 12 | CBIO CRESCENT BIOPHARMA INC. | 3.1% | $6.7m | 372,856 | 0% | held | |
| 13 | PCVX VAXCYTE INC | Healthcare | 2.9% | $6.2m | 107,223 | 13% | added |
| 14 | COGT COGENT BIOSCIENCES INC | Healthcare | 2.3% | $5.1m | 131,075 | -0% | held |
| 15 | VSTM VERASTEM INC | Healthcare | 2.3% | $5.0m | 1,306,800 | 0% | held |
| 16 | IRON DISC MEDICINE INC | Healthcare | 1.8% | $3.9m | 52,655 | 0% | held |
| 17 | PHVS PHARVARIS N V | Healthcare | 1.7% | $3.7m | 108,055 | – | new |
| 18 | ZLAB ZAI LAB LTD | Healthcare | 1.6% | $3.5m | 183,362 | 0% | held |
| 19 | BIOA BIOAGE LABS INC | 1.1% | $2.5m | 100,732 | – | new | |
| 20 | LB PHARMACEUTICALS INC | 1.0% | $2.2m | 68,249 | – | new | |
| 21 | EVMN EVOMMUNE INC | 0.7% | $1.6m | 119,063 | -35% | reduced | |
| 22 | ACET ADICET BIO INC | 0.6% | $1.4m | 157,827 | 0% | held |
What did NEXTBio Capital Management LP sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| 430 TERNS PHARMACEUTICALS INC | 71.3% | $31.9m |
| CMPX COMPASS THERAPEUTICS INC | 10.0% | $4.5m |
| OCULIS HOLDING AG | 8.9% | $4.0m |
| 4XC1 KALVISTA PHARMACEUTICALS INC | 5.9% | $2.7m |
| SMMT SUMMIT THERAPEUTICS INC | 3.8% | $1.7m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 85.3% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is NEXTBio Capital Management LP's portfolio?
Across every quarter NEXTBio Capital Management LP has filed, its median largest position is 13.6% of the book and its median top-ten weight is 74.4%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 5.0 completed holding spells, the median lasted 1.0 quarters; 22.0 positions are still open and their final length is unknown.